Stanford to limit drug maker financing
Stanford University is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school. The move is due to concern about the influence drug companies may have on medical education. Nearly all doctors in the country must take annual refresher courses that drug makers have long paid for, but Stanford will no longer let drug and device companies specify which courses they wish to finance. Instead, companies will be asked to contribute only to a schoolwide pool of money that can be used for any class, even ones that never mention a company's products.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- FDA hopes hospitals will switch to newly regulated pharmacies
- The 5 Biggest Healthcare Finance Trouble Spots
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- The Most Polarizing Topics in Healthcare IT
- Nonprofit Hospital Outlook 'Negative' in 2014
- How CPOE Will Make Healthcare Smarter
- Why You Should Involve Patients in Nursing Handoffs
- Are ACOs Really Different from HMOs?
- Safety Net Executives Renew Call to Preserve DSH Payments